The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Pregnancy-induced Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 105 participants.

Also called NCT01795248

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 105 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01795248
  • EudraCT 2012-001371-37
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Denmark (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01795248. Randomized; triple masking; primary purpose prevention. Start 2012-07 (actual); primary completion 2019-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Pregnancy-induced Diabetes
Condition
Gestational Diabetes Mellitus
Intervention (Drug)
Liraglutide
Intervention (Drug)
Placebo
Lead sponsor
Tina Vilsboll (class: other)
Collaborator
Novo Nordisk A/S (class: industry)
Collaborator
Copenhagen University Hospital, Rigshospitalet (class: other)
Collaborator
Hvidovre University Hospital (class: other)
Collaborator
Herlev Hospital (class: other)
Collaborator
Hillerod Hospital, Denmark (class: other)
Collaborator
University of Copenhagen (class: other)
Collaborator
The Novo Nordisk Foundation Center for Basic Metabolic Research (class: other)
Collaborator
Aarhus University Hospital (class: other)

Record details

Record id
cardio:ct-nct01795248
Content hash
cbac12809d7ab4197d5216488b948e949b6d099e483cf10c88e8c9f36f82b001